Clinical Trials | January 11, 2026
Merck initiates phase 3 trial of calderasib with Keytruda QLEX for NSCLC
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
DengiAll will be the first indigenous single-shot dengue vaccine in India and is expected to enter the markets by 2027
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
The study will run across 18 sites and enroll roughly 200 patients over 24 months
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
Subscribe To Our Newsletter & Stay Updated
